Galectin Therapeutics, Inc. (GALT) Stock Surges Following Success of Topline Data from Belapectin Clinical Trial
Galectin Therapeutics, Inc. (GALT) stock prices were down by a marginal 1.43% as of the market closing on July 8th, 2021, bringing it down to